
Dishman Carbogen Amcis Ltd. (DCAL) 52 Week Low Streak Deepens
Updated: 19 Nov 2026 • 11:54 am
Posted by:

Dishman Carbogen Amcis Ltd. has now set a fresh 52-week low for its second straight session, extending a streak that has taken the stock down 7.88% across the two-day run. The latest trough stood at Rs 119.3, while the latest traded price was Rs 119.85 at 19 November 2026 at 11:52 AM IST. Univest data confirms the repeated-low pattern, but it does not establish a company-specific cause for the continued decline.
With a market capitalisation of Rs 2,039.75 crore, the repeated-low pattern matters differently from a one-day breakdown because it shows that the stock has remained under pressure across consecutive sessions rather than reacting to a single move. For readers following the Dishman Carbogen Amcis Ltd. 52 Week Low Streak, the important question is not only where the share price stands now, but how the streak has altered valuation, sector comparison and the signals investors should monitor next.
Dishman Carbogen Amcis Ltd. 52 Week Low Streak: Consecutive Low Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 119.85 |
| Previous Close | Rs 121.25 |
| Today's Move | Rs -1.4 (-1.15%) |
| Open | Rs 121.1 |
| High | Rs 126.7 |
| Low | Rs 119.3 |
| Market Capitalisation | Rs 2,039.75 crore |
Dishman Carbogen Amcis Ltd. (DCAL) traded at Rs 119.85 versus the previous close of Rs 121.25, a fall of 1.15%. The stock opened at Rs 121.1, reached a high of Rs 126.7, touched a low of Rs 119.3.
Dishman Carbogen Amcis Ltd. was trading at Rs 119.85, down Rs 1.40 or 1.15% from the previous close of Rs 121.25. The stock opened at Rs 121.1, touched a high of Rs 126.7 and a low of Rs 119.3 during the session, which also marked the fresh 52-week low. The latest traded price sat very near the day’s bottom, showing that the Dishman Carbogen Amcis Ltd. 52 Week Low Streak remained intact through the morning session.
The price action leaves the stock with a narrow recovery from the day’s trough, but still below the previous close. For a reader tracking the Dishman Carbogen Amcis Ltd. 52 Week Low Streak, the key point is that the latest traded price did not move far away from the yearly low zone. That makes the streak more relevant than a single intraday dip, because the stock has repeated the low across sessions instead of recovering above the prior trough. Market capitalisation at Rs 2,039.75 crore places the move in a context where the valuation impact of every price change is visible in the share price and market cap together.
What the Repeated 52-Week Lows Show
The Dishman Carbogen Amcis Ltd. 52 Week Low Streak shows a confirmed multi-session downside pattern, not just an isolated weak day. Across the streak, the stock has declined 7.88%, which is the clearest way to read the move because it captures the full run rather than a single session. The current 52-week low of Rs 119.3 is also the latest reference point for the streak.
What this repeated pattern does not prove is just as important. The available numbers confirm the breakdown, but they do not identify a company-specific trigger behind it. So while the Dishman Carbogen Amcis Ltd. 52 Week Low Streak is real and visible in the price series, the data alone does not support a claim about whether the move was driven by a single announcement, a sector shift or broader market behaviour. Readers should treat the streak as a factual price signal first, and then test any explanation against fresh company updates.
Dishman Carbogen Amcis Ltd. (DCAL) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 2,039.75 crore |
| P/B Ratio | 0.29x |
| ROE | 1.56% |
| ROCE | 3.21% |
| EPS | Rs -7.39 |
| Book Value Per Share | Rs 425.5 |
| Dividend Yield | 0% |
Dishman Carbogen Amcis Ltd. (DCAL) fundamental metrics show P/B 0.29x, ROE 1.56%, ROCE 3.21%. These figures provide context only and are not a buy or sell signal.
Dishman Carbogen Amcis Ltd. has a market capitalisation of Rs 2,039.75 crore, which gives readers a sense of company size before judging valuation. On valuation, P/B at 0.29x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 1.56% and ROCE of 3.21%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs -7.39, book value per share of Rs 425.5, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 30.6x, median ROE of 11.23%, median ROCE of 13.1%. Taken together, they outline the fundamentals rather than a view on the stock.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Benchmark Median P/E | 30.6x |
| Benchmark Average P/E | 59.27x |
| Benchmark P/E Range | 2.71x to 1,378.1x |
| Company P/B Ratio | 0.29x |
| Benchmark Median P/B | 2.81x |
| Company ROE | 1.56% |
| Benchmark Median ROE | 11.23% |
| Company ROCE | 3.21% |
| Benchmark Median ROCE | 13.1% |
| Company Market Capitalisation | Rs 2,039.75 crore |
| Benchmark Median Market Cap | Rs 789.48 crore |
Dishman Carbogen Amcis Ltd. (DCAL) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Dishman Carbogen Amcis Ltd. (DCAL) has a ROE of 1.56%, which is below the benchmark median of 11.23%, a difference of -86.11%. Dishman Carbogen Amcis Ltd. (DCAL) has a ROCE of 3.21%, which is below the benchmark median of 13.1%, a difference of -75.5%.
Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Venus Remedies Ltd. | VENUSREM | 2,033.79 | 15.92 | 2.75 | 16.79 | 21.88 |
| Windlas Biotech Ltd. | WINDLAS | 2,060.94 | 30.7 | 3.64 | 12.52 | 16.06 |
| Indoco Remedies Ltd. | INDOCO | 2,073.47 | 69.7 | 2.18 | -10.13 | 0.79 |
| Beta Drugs Ltd. | BETA | 1,993.48 | 38.61 | 4.58 | 18.78 | 19.16 |
| Hester Biosciences Ltd. | HESTERBIO | 1,982.01 | 13.97 | 4.24 | 17.05 | 16.21 |
Its ROE of 1.56% compares with a peer median of 16.79% across the companies shown in the table. ROCE stood at 3.21% versus the displayed peer median of 16.21%, providing a capital-efficiency comparison. Dishman Carbogen Amcis Ltd. (DCAL) has a market capitalisation of Rs 2,039.75 crore. Among the 5 peers shown, 2 have a larger market capitalisation.
Why Investors Are Watching Dishman Carbogen Amcis Ltd.
- The Dishman Carbogen Amcis Ltd. 52 Week Low Streak is now a second straight session, so the price pattern has become more persistent than a single-day slip.
- The cumulative decline across the streak is 7.88%, which gives a fuller view than the latest session change alone.
- The current 52-week low of Rs 119.3 keeps the share price near its yearly trough and makes the latest traded level important to monitor.
- The stock’s P/B of 0.29 is far below the Healthcare sector median, so the valuation gap is wide even after the streak.
- ROE, ROCE and EPS remain weak in the latest Univest figures, so the price move is unfolding against a soft fundamental base.
About Dishman Carbogen Amcis Ltd.
Dishman Carbogen Amcis Ltd. operates in the Pharmaceuticals & Drugs industry within the Healthcare sector. For a reader tracking the Dishman Carbogen Amcis Ltd. 52 Week Low Streak, the key company context is that this is a business in a regulated healthcare segment where market pricing, earnings quality and return ratios matter closely. The current market capitalisation stands at Rs 2,039.75 crore, which gives a size context without changing the fact that the streak is being driven by price behaviour.
The company’s latest valuation and return metrics suggest that the share price is being assessed against a weak earnings backdrop rather than a strong operating read-through. That is why the Dishman Carbogen Amcis Ltd. 52 Week Low Streak should be read alongside book value, ROE, ROCE and sector comparisons rather than in isolation. The stock’s fresh one-year low is therefore both a price event and a valuation event.
Track Dishman Carbogen Amcis Ltd. Share Price on Univest
Use Dishman Carbogen Amcis Ltd. (DCAL) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.
Readers following the Dishman Carbogen Amcis Ltd. 52 Week Low Streak can keep tracking the share price, market capitalisation and valuation metrics as new sessions unfold. The most useful next checkpoints are whether the stock stabilises above the latest 52-week low, whether the cumulative decline extends further, and whether the fundamental ratios begin to move closer to the sector range. For now, the streak remains the main story.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why is Dishman Carbogen Amcis Ltd. hitting a 52-week low again?
Ans. The price has set a fresh 52-week low for a second straight session, but the latest Univest figures do not establish a specific company-level cause. The Dishman Carbogen Amcis Ltd. 52 Week Low Streak is confirmed by price action, not by.
How long is the Dishman Carbogen Amcis Ltd. 52 Week Low Streak?
Ans. The streak has run for two consecutive sessions. That means Dishman Carbogen Amcis Ltd. has set a new 52-week low on both sessions, making this a second straight session of yearly-low formation.
How much has Dishman Carbogen Amcis Ltd. moved across the streak?
Ans. The cumulative move across the Dishman Carbogen Amcis Ltd. 52 Week Low Streak is -7.88%. That figure is the cleanest way to read the run because it captures the full streak rather than only the latest session.
What is the current 52-week low for Dishman Carbogen Amcis Ltd.?
Ans. The current fresh 52-week low is Rs 119.3. The latest traded price of Rs 119.85 remained close to that level, which shows the streak is still active around the low zone.
Is Dishman Carbogen Amcis Ltd. low-valued on valuation after the streak?
Ans. The stock’s P/B ratio is 0.29, which is far below the sector median shown in the data. However, the low multiple needs to be read with weak return ratios and negative EPS, so the streak does not automatically make the.
How does Dishman Carbogen Amcis Ltd. compare with healthcare peers?
Ans. Its P/B is far below peers such as Venus Remedies, Windlas Biotech, Beta Drugs and Hester Biosciences. The Dishman Carbogen Amcis Ltd. 52 Week Low Streak has therefore pushed the stock into a much lower valuation band than many displayed.
What do ROE and ROCE say in this case?
Ans. ROE at 1.56% and ROCE at 3.21% are both below the sector medians. Those figures suggest that the share price is sitting near a low point while return ratios remain weak relative to the industry sample.
Does the streak prove the reason for the decline?
Ans. No. The Dishman Carbogen Amcis Ltd. 52 Week Low Streak confirms a repeated price pattern, but it does not by itself prove why the stock kept making new lows. A separate company update would be needed to support a cause.
What should investors watch next?
Ans. Investors should watch whether the stock remains above the latest 52-week low, whether the cumulative decline extends, and whether valuation and return ratios start to move closer to the sector norm. The streak itself remains the main signal.
Recent Articles

Crude Oil Price Today: Brent Steadies Near $92, WTI at $82 After Sharp Fall as Supply Surplus and US Stockpile Build Weigh
19 November 2026

Sensex Today Recovers 556 Points From Day's Low, Nifty Reclaims 25,300 as Auto Rally and FII Buying Offset Hawkish Fed Minutes
19 November 2026

Maruti Suzuki Share Price Jumps 6% as Nifty Auto Surges 3.6%; M&M, Hero MotoCorp, TVS Motor and Eicher Rally on Softer Crude
19 November 2026

LT Foods Share Price Jumps Up to 10% as Daawat Maker Buys US Brand Maya Kaimal for $5.8 Million
19 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Crude Oil Price Today: Brent Steadies Near $92, WTI at $82 After Sharp Fall as Supply Surplus and US Stockpile Build Weigh
Sensex Today Recovers 556 Points From Day's Low, Nifty Reclaims 25,300 as Auto Rally and FII Buying Offset Hawkish Fed Minutes
Maruti Suzuki Share Price Jumps 6% as Nifty Auto Surges 3.6%; M&M, Hero MotoCorp, TVS Motor and Eicher Rally on Softer Crude
LT Foods Share Price Jumps Up to 10% as Daawat Maker Buys US Brand Maya Kaimal for $5.8 Million
ICICI Life Insurance (ICICILIFE) Share Price Rises 2.04% Today

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





